Axsome aims for FDA filing in Alzheimer’s agitation

The latest stories trending on MedCity News.

Editor's Pick

Top Story Axsome Aims for FDA Filing in Alzheimer's Agitation Despite Mixed Bag of Phase 3 Data One Phase 3 test of Auvelity met its main goal in Alzheimer's agitation while the drug's other pivotal trial showed numerical improvement that fell short of statistical significance. Axsome Therapeutics aims to offer an alternative to Rexulti, a Lundbeck and Otsuka Pharmaceutical product that is the only FDA-approved Alzheimer's agitation drug. Skip the Store - Enjoy Delicious Organic Meals Delivered to Your Door! Join Now for 50% Off Your First Month and Free Salads for Two Months! What Makes Green Chef Stand Out? 100% Organic Ingredients: Savory meals crafted from entirely organic ingredients, free from GMOs and harmful pesticides. Effortless Meal Prep: Enjoy quick and easy cooking with pre-measured and prepared ingredients. Variety of Choices: Select from over 80 delicious meals each week, accommodating various dietary preferences.

Featured News

Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs December saw a slew of executive hires, promotions, exits and layoffs across the healthcare industry. For example, companies like Humana and Mayo Clinic hired new C-suite leaders, organizations including Atlantic Health System and Amwell are saying goodbye to key executives, and firms like CVS Health and Optum announced rounds of job cuts. Axsome Aims for FDA Filing in Alzheimer's Agitation Despite Mixed Bag of Phase 3 Data One Phase 3 test of Auvelity met its main goal in Alzheimer's agitation while the drug's other pivotal trial showed numerical improvement that fell short of statistical significance. Axsome Therapeutics aims to offer an alternative to Rexulti, a Lundbeck and Otsuka Pharmaceutical product that is the only FDA-approved Alzheimer's agitation drug. Uno Health Unveils Tool to Help Americans Check Eligibility for Financial Benefits The Uno Savings Guide is a free resource that helps people check their eligibility for financial benefit programs, like Medicaid, Medicare Savings Programs and SNAP. Bristol Myers Squibb Wins FDA Nod for Injectable Version of Blockbuster Cancer Drug Opdivo Qvantig, administered by injection in less than five minutes, is now FDA approved for solid tumor indications covered by Opdivo, a 30-minute intravenous infusion. The new product will help Bristol Myers Squibb compete with biosimilars as Opdivo faces looming patent expiration. The Same Processes that Make Smartphones a Risk for Young People Must Be Harnessed to Provide Beneficial Digital Medical Treatments For All Addressing difficult-to-treat diseases and disorders, quickly, safely, and with little to no side effects is a positive boon to our overburdened health system. 2025 Trends to Watch in Patient Payments While worries about the affordability of care are sure to persist for many Americans over the coming year, here are some other patient payment trends for providers to watch

Resources

MedCity FemFwd: How Celmatix is Using ARPA-H's Sprint for Women's Health Funding In this episode, we're joined by Dr. Piraye Yurttas Beim, founder and CEO of Celmatix, a women's health biotech company. Celmatix was recently awarded $3.5 million from the Advanced Research Projects Agency for Health (ARPA-H) through the Sprint for Women's Health program. In this episode, Beim discusses how Celmatix will be using the funding. Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe